Cabaletta Bio, Inc.

CABA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $83.0M $164.0M $193.2M $81.6M $122.2M $101.4M $136.2M $33.0M
Accounts Receivable — — — — — — — —
Inventory — — — — — — — —
Total Current Assets $138.9M $166.7M $244.5M $108.8M $124.5M $113.5M $140.6M $34.0M
Property, Plant & Equipment $1.9M $2.7M $2.5M $2.6M $1.4M $890.0K $815.0K —
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $165.1M $185.0M $253.7M $117.0M $126.3M $114.7M $141.5M $34.2M
Liabilities
Accounts Payable $6.6M $4.9M $4.5M $2.5M $2.3M $1.2M $920.0K $603.0K
Total Current Liabilities $50.2M $27.1M $16.0M $9.5M $8.4M $5.2M $3.1M $943.0K
Long-Term Debt — — — — — — — —
Total Liabilities $53.0M $32.7M $17.5M $12.4M $8.4M $5.2M $3.1M $44.9M
Stockholders' Equity
Retained Earnings $-517.0M $-349.1M $-233.2M $-165.6M $-112.6M $-66.3M $-33.0M $-12.5M
Total Stockholders' Equity $112.1M $152.3M $236.2M $104.5M $118.0M $109.5M $138.3M $-10.7M